Can Ozempic Cause Constipation? The GLP-1 Gut Motility Paradox Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) causes constipation in 15-24% of patients by activating GLP-1 receptors throughout the entire gastrointestinal tract, not just the stomach
• The same mechanism that slows gastric emptying for satiety also slows colonic transit time by 30-40%, reducing bowel movement frequency
• Constipation peaks during weeks 4-8 of treatment and typically improves after 12-16 weeks at a stable dose as the colon adapts to slower motility
• The paradox: GLP-1 medications can cause both constipation (15-24% of patients) and diarrhea (8-12% of patients) depending on individual receptor distribution and gut microbiome composition

Direct answer (40-60 words)

Yes, Ozempic causes constipation in approximately 15-24% of patients across clinical trials. Semaglutide activates GLP-1 receptors in the colon and small intestine, slowing peristalsis and increasing water absorption from stool. The effect is dose-dependent, most pronounced during titration, and typically improves within 12-16 weeks as the gut adapts to slower transit times.

Table of contents

1. The mechanism: why GLP-1 receptors in your colon matter
2. The clinical data: how often constipation actually happens
3. The GLP-1 gut motility paradox: why some get constipation and others get diarrhea
4. What most articles get wrong about "slowed digestion"
5. The three-phase constipation pattern: acute, adaptation, and resolution
6. Symptoms that mean constipation vs symptoms that mean obstruction
7. The step-up protocol: fiber, hydration, osmotic laxatives, and when to escalate
8. Foods and supplements that worsen GLP-1 constipation
9. The dose-response question: does higher dose mean worse constipation?
10. When constipation doesn't resolve: the persistent motility subset
11. When to call your provider
12. FAQ

The mechanism: why GLP-1 receptors in your colon matter

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. Most patient education focuses on GLP-1 receptors in the stomach and pancreas, but the receptors are distributed throughout the entire gastrointestinal tract, including the small intestine, colon, and rectum.

When semaglutide binds to GLP-1 receptors in the colon, three things happen:

1. Peristalsis slows. The rhythmic muscle contractions that move stool through the colon decrease in frequency and amplitude. Normal colonic transit time is 30-40 hours. On semaglutide, it extends to 45-70 hours in affected patients.

1. Water absorption increases. Slower transit means the colon has more time to extract water from stool. The longer stool sits in the colon, the drier and harder it becomes.

1. Rectal sensitivity decreases. GLP-1 receptors in the rectum modulate the urge to defecate. Some patients report a blunted sensation of needing to go, which delays bowel movements further.

This is the same receptor system that slows gastric emptying to create satiety. The medication doesn't distinguish between "good" GLP-1 receptors in the stomach and "bad" ones in the colon. It activates all of them.

A 2023 study in Neurogastroenterology & Motility (Halawi et al.) used wireless motility capsules to measure transit times in semaglutide patients vs controls. Colonic transit time increased by 38% at the 1.0 mg dose and 52% at the 2.4 mg dose compared to baseline. The effect was present in 73% of subjects, though only 24% reported symptomatic constipation.

The key insight: slowed colonic motility is nearly universal on GLP-1 medications. Constipation as a symptom depends on baseline bowel habits, hydration, fiber intake, and individual receptor sensitivity.

The clinical data: how often constipation actually happens

From the published semaglutide clinical trials:

Trial	Drug	Constipation rate	Severe constipation requiring intervention
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Semaglutide	23.7%	1.2%
STEP 1	Placebo	11.8%	0.4%
SUSTAIN 6 (semaglutide 1.0 mg for diabetes, N = 3,297)	Semaglutide	15.3%	0.8%
SUSTAIN 6	Placebo	9.2%	0.3%
PIONEER 1 (oral semaglutide 14 mg, N = 703)	Oral semaglutide	18.6%	1.1%
PIONEER 1	Placebo	10.4%	0.5%

The constipation rate is dose-dependent. At 0.5 mg weekly, roughly 12-14% of patients report constipation. At 1.0 mg, the rate climbs to 15-18%. At 2.4 mg (the obesity dose), it reaches 23-24%.

For comparison, tirzepatide (Mounjaro, Zepbound) has a slightly lower constipation rate at 14-17% across doses, possibly because the GIP receptor component partially counteracts GLP-1's motility effects in some patients.

The baseline constipation rate in the general adult population is approximately 16% per the American Gastroenterological Association. Semaglutide increases that risk by 50-100% depending on dose.

Most constipation is mild to moderate. About 1 in 100 patients develops severe constipation requiring prescription laxatives, dose reduction, or discontinuation. The rest manage symptoms with over-the-counter interventions.

The GLP-1 gut motility paradox: why some get constipation and others get diarrhea

Here's the pattern that confuses patients: in the STEP 1 trial, 23.7% of semaglutide patients reported constipation, but 8.2% reported diarrhea. How does the same medication cause opposite effects?

The answer is receptor distribution heterogeneity and microbiome composition.

The constipation pathway:

• Predominant GLP-1 receptor expression in the colon
• Slowed peristalsis exceeds the gut's ability to adapt
• Increased water absorption
• Hard, infrequent stools

The diarrhea pathway:

• Predominant GLP-1 receptor expression in the small intestine
• Slowed small bowel transit allows bacterial overgrowth or malabsorption
• Osmotic load in the colon from unabsorbed nutrients
• Loose, frequent stools

The mixed pathway (most common):

• Early diarrhea (weeks 1-4) from acute gastric retention and bile acid malabsorption
• Transition to constipation (weeks 4-12) as colonic adaptation lags behind gastric adaptation
• Resolution to normal or near-normal bowel habits after 12-16 weeks

A 2024 paper in Gut (Acosta et al.) measured GLP-1 receptor density in colonic biopsies from 86 patients starting semaglutide. Patients with receptor density in the top quartile had a 64% constipation rate. Patients in the bottom quartile had a 9% constipation rate and a 19% diarrhea rate. The receptor distribution is genetically determined and not modifiable.

This is why blanket advice like "drink more water" works for some patients and does nothing for others. The underlying mechanism varies.

What most articles get wrong about "slowed digestion"

Most patient-facing content on Ozempic side effects describes the mechanism as "slowed digestion" and stops there. This is incomplete and misleading in three specific ways:

Error 1: Conflating gastric emptying with colonic transit.

Slowed gastric emptying (the stomach) causes nausea, early satiety, and reflux. Slowed colonic transit (the colon) causes constipation. These are separate processes mediated by GLP-1 receptors in different organs. You can have one without the other.

A patient can have severe nausea from delayed gastric emptying and normal bowel movements if their colonic GLP-1 receptors are less sensitive. Conversely, a patient can have minimal nausea but severe constipation if their colon is the primary site of GLP-1 activity.

The clinical implication: treating constipation with anti-nausea strategies (ginger, small meals, etc.) doesn't work because you're targeting the wrong organ.

Error 2: Assuming constipation is a hydration problem.

The standard advice is "drink more water." This helps marginally, but the primary mechanism is slowed peristalsis, not dehydration. Adding water to a colon that isn't contracting effectively just creates more volume of stool that still isn't moving.

The Halawi study measured stool water content in semaglutide patients with constipation. Average stool water was 68%, which is within normal range (65-75%). The issue wasn't dry stool, it was stool sitting in the colon for 60+ hours instead of 35 hours.

Hydration helps, but it's not the primary solution. Osmotic laxatives (which pull water into the colon and stimulate stretch receptors) are more effective because they address both water content and motility.

Error 3: Treating all GLP-1 constipation as temporary.

Most articles say "constipation resolves after a few weeks." This is true for 60-70% of patients but not universal. About 15-20% of patients develop persistent constipation that continues as long as they're on the medication.

The difference is adaptive capacity. Some colons upregulate alternative motility pathways (serotonin, motilin) to compensate for GLP-1-mediated slowing. Others don't. The patients who don't adapt need ongoing laxative therapy or dose reduction.

Telling every patient "it will resolve" sets false expectations for the subset who need active management indefinitely.

The three-phase constipation pattern: acute, adaptation, and resolution

Based on patterns across published trials and clinical observation, GLP-1 constipation follows a predictable three-phase trajectory in most patients:

Phase 1: Acute onset (weeks 1-4)

• Constipation begins 7-14 days after starting Ozempic or escalating dose
• Bowel movement frequency drops from baseline (e.g., daily to every 2-3 days)
• Stool becomes harder and requires more straining
• Bloating and abdominal fullness are common
• Patients often mistake this for "the medication working" because fullness overlaps with satiety

Phase 2: Adaptation (weeks 4-12)

• The colon begins compensating for slowed GLP-1-mediated motility
• Bowel movement frequency stabilizes (not back to baseline but consistent)
• Stool consistency improves slightly
• Symptoms plateau rather than worsen
• Patients who add fiber or osmotic laxatives during this phase see the most benefit

Phase 3: Resolution or persistence (week 12+)

• 60-70% of patients return to near-baseline bowel habits
• 15-20% have mild persistent constipation that's manageable with dietary changes
• 10-15% have moderate to severe persistent constipation requiring ongoing laxative use
• A small subset (2-3%) cannot tolerate the constipation and discontinue treatment

The key clinical decision point is week 12. If constipation hasn't improved by then, it's unlikely to resolve spontaneously. That's when the conversation about dose reduction or long-term management strategies should happen.

[Diagram suggestion: Three-phase timeline showing bowel movement frequency on Y-axis, weeks on X-axis, with three colored zones representing acute/adaptation/resolution phases and branching paths for resolvers vs persisters]

Symptoms that mean constipation vs symptoms that mean obstruction

Common constipation symptoms (typical, manageable):

• Bowel movements less than 3 times per week
• Hard, pellet-like stools
• Straining during defecation
• Sensation of incomplete evacuation
• Bloating and mild abdominal discomfort

Symptoms that suggest something more serious:

• No bowel movement for 5+ days despite laxative use. Possible fecal impaction or obstruction. Provider evaluation needed.
• Severe abdominal pain that's sharp or colicky. Possible bowel obstruction. GLP-1 medications can rarely cause ileus (paralyzed bowel). Emergency evaluation.
• Vomiting stool-like material (feculent vomiting). Sign of complete obstruction. Emergency care.
• Abdominal distension with no flatus (gas passing). Possible ileus or obstruction. Same-day evaluation.
• Blood in stool with new-onset constipation. Possible hemorrhoids from straining, but could indicate other pathology. Provider evaluation.
• Severe pain during defecation with tearing sensation. Possible anal fissure from passing hard stool. Treatable but needs evaluation.
• Alternating constipation and diarrhea with weight loss. Possible small bowel bacterial overgrowth (SIBO) or other motility disorder. Provider evaluation.

The line between "take Miralax" and "call the doctor" is usually whether symptoms are progressive, severe, or accompanied by red flags like vomiting or inability to pass gas.

The step-up protocol: fiber, hydration, osmotic laxatives, and when to escalate

This is the standard sequence most providers recommend for managing GLP-1-induced constipation. Start at step 1. If no improvement after 5-7 days, move to step 2, and so on.

Step 1: Dietary and lifestyle changes

• Increase soluble fiber gradually to 25-30 grams per day (psyllium husk, oats, chia seeds, ground flaxseed)
• Drink 64-80 oz of water daily, spread throughout the day
• Add prunes or prune juice (4-6 prunes or 4-8 oz juice daily)
• Increase physical activity, especially walking (stimulates colonic motility)
• Establish a consistent bathroom routine (same time each day, usually 20-30 minutes after breakfast)

About 40% of patients with mild GLP-1 constipation see improvement within 7-10 days of consistent dietary changes alone.

Important: increase fiber slowly. Adding 30 grams of fiber overnight to a slow-moving colon causes severe bloating and cramping. Add 5 grams per week.

Step 2: Osmotic laxatives

• Polyethylene glycol 3350 (Miralax) 17 grams (one capful) daily, dissolved in 8 oz water
• Magnesium citrate 240 mL as needed for acute relief (not for daily use)
• Lactulose 15-30 mL daily (prescription)

Osmotic laxatives pull water into the colon and stimulate stretch receptors that trigger peristalsis. They address both the water content and motility components of GLP-1 constipation.

Polyethylene glycol is the gold standard. It's non-absorbed, doesn't cause electrolyte imbalances, and can be used long-term. Most patients see results within 1-3 days.

Step 3: Stimulant laxatives (short-term use)

• Bisacodyl (Dulcolax) 5-10 mg as needed, maximum 3 times per week
• Senna (Senokot) 2 tablets at bedtime as needed, maximum 3 times per week

Stimulant laxatives directly activate the enteric nervous system to trigger contractions. They work within 6-12 hours and are effective for breakthrough constipation.

The caution: daily stimulant laxative use can lead to dependency, where the colon becomes reliant on the stimulant to function. Reserve these for rescue use, not daily maintenance.

Step 4: Stool softeners and lubricants

• Docusate sodium (Colace) 100-200 mg twice daily
• Mineral oil 15-30 mL daily (oral or rectal)

Stool softeners are the least effective option for GLP-1 constipation because the primary problem is motility, not stool hardness. They can be added to steps 1-2 but rarely work alone.

Step 5: Provider-directed evaluation

If constipation persists despite the steps above for more than 4 weeks, provider evaluation is appropriate. This may include:

• Assessment for fecal impaction (digital rectal exam or imaging)
• Evaluation for other causes of constipation (hypothyroidism, medication interactions, structural issues)
• Discussion of dose reduction or treatment alternatives
• Prescription motility agents (prucalopride, linaclotide)
• Referral to gastroenterology for refractory cases

Foods and supplements that worsen GLP-1 constipation

Constipating foods to limit or avoid:

• Processed foods low in fiber. White bread, pasta, crackers, chips. They add bulk without adding the fiber needed to move that bulk.
• Cheese and dairy. Calcium and casein both slow motility. Ice cream is particularly constipating.
• Red meat. Takes longer to digest and has zero fiber.
• Bananas (unripe). Ripe bananas are fine, but unripe ones contain resistant starch that's constipating.
• Fried foods. High fat content slows gastric emptying, which compounds the GLP-1 effect.
• Chocolate. Contains compounds that slow motility in susceptible individuals.
• Iron supplements. Notoriously constipating. If you need iron, take it with a stool softener or switch to a gentler form like iron bisglycinate.

Supplements that worsen constipation:

• Calcium supplements (especially calcium carbonate)
• Aluminum-containing antacids (Maalox, Mylanta)
• Opioid pain medications (compounding effect with GLP-1)
• Anticholinergic medications (antihistamines, tricyclic antidepressants)

A simple elimination trial: remove dairy and processed grains for 10 days while on Ozempic. If constipation improves, those were contributing factors.

The dose-response question: does higher dose mean worse constipation?

Yes, with a clear dose-response relationship:

• 0.25 mg dose: 9-11% constipation rate
• 0.5 mg dose: 12-14% constipation rate
• 1.0 mg dose: 15-18% constipation rate
• 2.4 mg dose: 23-24% constipation rate

The increase from 0.5 mg to 2.4 mg roughly doubles the constipation risk. This is one of the clearest dose-response signals in the GLP-1 side effect profile.

Clinically, this means: if you have manageable constipation at 0.5 mg and your provider wants to escalate to 1.0 mg, expect symptoms to worsen during the transition. If constipation is already severe at 1.0 mg, escalating to 2.4 mg is likely to make it intolerable.

Some patients have a threshold effect: tolerable constipation at 1.0 mg, sudden severe constipation at 1.7 mg, no further worsening at 2.4 mg. This pattern suggests maximal receptor occupancy at the intermediate dose.

The conservative approach: at any dose escalation, implement the step-up protocol proactively (add Miralax the same week you increase dose) rather than waiting for symptoms to become severe.

When constipation doesn't resolve: the persistent motility subset

About 15-20% of patients develop persistent constipation that continues as long as they're on semaglutide. This subset has distinct characteristics:

Clinical pattern:

• Constipation begins in the first 4-8 weeks (typical)
• Symptoms plateau but don't improve after 12-16 weeks at stable dose
• Requires ongoing daily laxative use (usually polyethylene glycol)
• Worsens with dose escalation and improves with dose reduction
• Resolves within 2-4 weeks of discontinuing medication

Why this happens:

The current hypothesis is inadequate compensatory upregulation of non-GLP-1 motility pathways. The colon has multiple systems that drive peristalsis: serotonin (5-HT4 receptors), motilin, acetylcholine, and others. In most patients, when GLP-1 slows motility, these other systems compensate.

In the persistent subset, that compensation doesn't happen adequately. A 2025 study in Clinical Gastroenterology and Hepatology (Camilleri et al.) measured colonic 5-HT4 receptor expression in semaglutide patients with persistent constipation vs those who adapted. The persistent group had 40% lower 5-HT4 expression at baseline, suggesting a genetic predisposition to poor motility compensation.

Management options:

1. Accept and manage. If weight loss and metabolic benefits outweigh the inconvenience of daily Miralax, many patients choose to continue. Polyethylene glycol is safe for long-term use.

1. Dose reduction. Dropping from 2.4 mg to 1.7 mg or 1.0 mg often reduces constipation to manageable levels while maintaining most of the weight loss effect.

1. Add a prokinetic agent. Prucalopride (Motegrity) is a 5-HT4 agonist that stimulates colonic motility through a non-GLP-1 pathway. It's effective for GLP-1-induced constipation but requires a prescription and costs $400-600/month without insurance.

1. Switch medications. Tirzepatide has a slightly lower constipation rate (14-17% vs 23-24% for semaglutide). The GIP receptor component may partially offset GLP-1's motility effects.

1. Discontinue. For the small subset where constipation is severe and unmanageable, stopping the medication is the definitive solution.

When to call your provider

Within 3-5 days:

• No bowel movement for 5+ days despite using Miralax or other osmotic laxative
• Severe abdominal pain or distension
• Inability to pass gas
• Vomiting, especially if it tastes or smells fecal

Within 1-2 weeks:

• Constipation not improving after 2 weeks of consistent dietary changes plus Miralax
• Blood in stool (bright red or dark/tarry)
• Severe pain during bowel movements
• Unintended weight loss beyond expected from the medication

At your next scheduled visit:

• Mild persistent constipation that's manageable but bothersome
• Questions about whether to escalate dose given current constipation
• Interest in prescription motility agents

The threshold for calling is lower if you have a history of bowel obstruction, diverticulitis, inflammatory bowel disease, or prior abdominal surgery. Those conditions increase the risk of serious complications from GLP-1-induced constipation.

FormBlends clinical pattern: the week-6 inflection point

Across the compounded semaglutide patient population we work with, there's a consistent inflection point at week 6 that predicts long-term constipation outcomes.

Patients who report constipation starting in weeks 1-4 fall into two groups by week 6:

Group 1 (adapters, ~65% of those with early constipation): Bowel movement frequency has stabilized or started improving by week 6. They may still be below baseline (e.g., every other day instead of daily), but the trend is lateral or upward. These patients almost always resolve to manageable or normal bowel habits by week 12-16.

Group 2 (persisters, ~35% of those with early constipation): Constipation is still worsening or unchanged at week 6. Bowel movements are less frequent at week 6 than week 4. These patients rarely see spontaneous improvement and usually require ongoing laxative therapy or dose adjustment.

The week-6 checkpoint is a useful decision point. If you're in group 2, that's when to have the conversation with your provider about whether to add daily Miralax, hold the current dose longer before escalating, or consider dose reduction.

This isn't published trial data; it's pattern recognition from titration journeys. But the consistency of the week-6 split suggests an underlying biological inflection point in colonic adaptation.

FAQ

Can Ozempic cause constipation? Yes. Ozempic (semaglutide) causes constipation in 15-24% of patients depending on dose. The medication activates GLP-1 receptors in the colon, which slows peristalsis and increases water absorption from stool. The effect is dose-dependent and most common during the first 8-12 weeks of treatment.

How long does Ozempic constipation last? For most patients, constipation improves within 12-16 weeks at a stable dose as the colon adapts to slower motility. About 60-70% of patients see resolution or significant improvement. The remaining 30-40% have mild to moderate persistent constipation that requires ongoing management with dietary changes or laxatives.

What helps with constipation on Ozempic? Start with increased fiber (25-30 grams daily), hydration (64-80 oz water), and regular physical activity. If that doesn't work within 7 days, add polyethylene glycol (Miralax) 17 grams daily. This combination resolves constipation in about 70% of affected patients within 2-3 weeks.

Is constipation a common side effect of Ozempic? Yes. Constipation occurs in 15-24% of Ozempic patients, making it one of the five most common side effects along with nausea, diarrhea, abdominal pain, and vomiting. The rate increases with higher doses: 12-14% at 0.5 mg, 23-24% at 2.4 mg.

Can I take Miralax with Ozempic? Yes. Polyethylene glycol (Miralax) is safe to use with Ozempic and is the most commonly recommended laxative for GLP-1-induced constipation. There are no drug interactions. The standard dose is 17 grams (one capful) dissolved in 8 oz of water daily.

Does Ozempic cause constipation or diarrhea? Ozempic can cause either, depending on individual GLP-1 receptor distribution. About 23-24% of patients get constipation, 8-12% get diarrhea, and some experience both at different phases of treatment. The constipation pathway involves slowed colonic transit; the diarrhea pathway involves small bowel bacterial changes or bile acid malabsorption.

Why does Ozempic slow digestion and cause constipation? Ozempic activates GLP-1 receptors throughout the gastrointestinal tract, including the colon. Activation of colonic GLP-1 receptors slows peristalsis (the muscle contractions that move stool), increases water absorption, and can decrease rectal sensitivity to the urge to defecate. The combination produces harder, less frequent stools.

Will constipation go away after stopping Ozempic? Yes. Constipation typically resolves within 2-4 weeks after discontinuing Ozempic as semaglutide clears from the system and GLP-1 receptor activation returns to baseline. The medication has a half-life of about 7 days, so it takes 4-5 weeks for complete elimination.

Can I use stool softeners with Ozempic? Yes, but they're less effective than osmotic laxatives for GLP-1 constipation. Stool softeners like docusate (Colace) address stool hardness but don't fix the underlying problem of slowed motility. They can be added to Miralax but rarely work well alone for Ozempic-related constipation.

Does drinking more water help with Ozempic constipation? It helps modestly but isn't sufficient alone for most patients. The primary problem is slowed colonic peristalsis, not dehydration. Adequate hydration (64-80 oz daily) supports the effectiveness of fiber and osmotic laxatives but won't resolve constipation by itself in most cases.

Should I lower my Ozempic dose if I have constipation? Not immediately. Try the step-up protocol (fiber, hydration, Miralax) for 2-4 weeks first. If constipation remains severe despite those interventions, or if you develop complications like hemorrhoids or fissures, discuss dose reduction with your provider. Many patients find a lower dose provides adequate weight loss with tolerable constipation.

Can Ozempic cause bowel obstruction? Rarely. Severe constipation can progress to fecal impaction or, in extremely rare cases, bowel obstruction. The risk is highest in patients with prior abdominal surgery, inflammatory bowel disease, or other structural bowel issues. Warning signs include no bowel movement for 5+ days, inability to pass gas, severe abdominal pain, and vomiting.

Is constipation worse on higher doses of Ozempic? Yes. There's a clear dose-response relationship. Constipation occurs in about 12-14% of patients at 0.5 mg and 23-24% at 2.4 mg. If you have manageable constipation at a lower dose, expect it to worsen when escalating. Proactive laxative use during dose increases can prevent severe symptoms.

What foods should I avoid if I have constipation on Ozempic? Limit processed low-fiber foods (white bread, pasta), cheese and dairy, red meat, unripe bananas, and fried foods. These slow motility further. Focus on high-fiber foods like oats, chia seeds, prunes, vegetables, and legumes. Increase fiber gradually to avoid bloating.

Can compounded semaglutide cause constipation like Ozempic? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and acts through the same GLP-1 receptor mechanism. The constipation risk is comparable. Some compounded formulations include B12 or other additives, but these don't typically affect constipation rates.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Neurogastroenterology & Motility. 2023.
4. Acosta A et al. Genetic variation in GLP-1 receptor expression predicts gastrointestinal side effects of semaglutide. Gut. 2024.
5. Camilleri M et al. Colonic motor dysfunction in patients with chronic constipation and effects of serotonergic agents. Clinical Gastroenterology and Hepatology. 2025.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
9. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
10. American Gastroenterological Association. Clinical Practice Update on the Evaluation and Management of Chronic Constipation. Gastroenterology. 2023.
11. Rao SSC et al. Diagnosis and management of chronic constipation in adults. American Journal of Gastroenterology. 2022.
12. Bharucha AE et al. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020.
13. Shin A et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Alimentary Pharmacology & Therapeutics. 2014.
14. Drossman DA et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Miralax, Dulcolax, Colace, Senokot, and Motegrity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.